FY2025 EPS Estimates for Zura Bio Increased by HC Wainwright

Key Points

• HC Wainwright has raised its FY2025 EPS estimates for Zura Bio to ($0.74) from ($0.76), maintaining a "Neutral" rating with a price target of $2.00.
• Zura Bio reported a quarterly EPS of ($0.17), beating the consensus estimate of ($0.19), indicating a positive outlook from recent performance.
• Institutional investors have increased their holdings in Zura Bio, with 61.14% of the company's stock now owned by institutional investors and hedge funds.

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for Zura Bio in a note issued to investors on Tuesday, August 19th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.74) per share for the year, up from their previous estimate of ($0.76). HC Wainwright currently has a "Neutral" rating and a $2.00 target price on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share.

Other research analysts have also issued reports about the company. Chardan Capital reiterated a "buy" rating and set a $10.00 price objective on shares of Zura Bio in a research note on Friday, August 15th. Oppenheimer cut their price objective on Zura Bio from $17.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $14.00.

Zura Bio Price Performance

Shares of NASDAQ ZURA traded down $0.02 during trading hours on Thursday, reaching $2.03. The stock had a trading volume of 109,901 shares, compared to its average volume of 513,553. The business's fifty day moving average is $1.44 and its two-hundred day moving average is $1.32. The company has a market cap of $131.99 million, a price-to-earnings ratio of -2.91 and a beta of -0.06. Zura Bio has a twelve month low of $0.97 and a twelve month high of $5.07.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02.

Institutional Trading of Zura Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company's stock worth $4,893,000 after purchasing an additional 2,052,732 shares during the period. ADAR1 Capital Management LLC increased its position in Zura Bio by 34.9% in the first quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock worth $3,614,000 after purchasing an additional 723,933 shares during the period. Allostery Investments LP increased its position in Zura Bio by 44.2% in the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock worth $3,005,000 after purchasing an additional 714,258 shares during the period. Armistice Capital LLC increased its position in Zura Bio by 2.4% in the first quarter. Armistice Capital LLC now owns 1,536,000 shares of the company's stock worth $1,981,000 after purchasing an additional 36,000 shares during the period. Finally, Geode Capital Management LLC increased its position in Zura Bio by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock worth $2,389,000 after purchasing an additional 42,801 shares during the period. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.